Common Stock, par value $0.0001 per share

Edgewise Therapeutics, Inc.

1715 38th St., Boulder, CO, 80301

Novo Holdings A/S beneficially owns 5,350,000 shares of common stock representing approximately 4.98% of the Issuer's outstanding shares of common stock, based upon 107,532,173 shares of common stock outstanding as of April 9, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 23, 2026. Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the Reporting Person's cover page has been rounded down to 4.9%.

Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

Novo Holdings A/S has not effected any transactions in the Issuer's common stock within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's common stock within the past 60 days.

Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on April 23, 2026.